9.0.0.0 Ref­er­ences

1. Amer­i­can Di­a­betes As­so­ci­a­tion. Di­ag­no­sis and clas­sification of di­a­betes mel­li­tus. Di­a­betes Care 2014;37(Suppl. 1):S81–S90
2. Dabe­lea D, Rew­ers A, Staf­ford JM, et al.; SEARCH for Di­a­betes in Youth Study Group. Trends in the preva­lence of ke­toaci­do­sis at di­a­betes di­ag­no­sis: the SEARCH for Di­a­betes in Youth Study. Pe­di­atrics 2014;133:e938–e945
3. New­ton CA, Raskin P. Di­a­bet­ic ke­toaci­do­sis in type 1 and type 2 di­a­betes mel­li­tus: clin­i­cal and bio­chem­i­cal dif­ferences. Arch In­tern Med 2004; 164:1925–1931
4. Skyler JS, Bakris GL, Boni­fa­cio E, et al. Dif­fer­entiationof di­a­betes by patho­phys­i­ol­o­gy, nat­u­ral his­to­ry, and prog­no­sis. Di­a­betes 2017;66:241– 255
5. Insel RA, Dunne JL, Atkin­son MA, et al. Stag­ing presymp­tomat­ic type 1 di­a­betes: a sci­en­tific state­ment of JDRF, the En­docrine So­ci­ety, and the Amer­i­can Di­a­betes As­so­ci­a­tion. Di­a­betes Care 2015;38:1964–1974
6. In­ter­na­tion­al Ex­pert Com­mit­tee. In­ter­na­tion­al Ex­pert Com­mit­tee re­port on the role of the A1C assay in the di­ag­no­sis of di­a­betes. Di­a­betes Care 2009;32:1327–1334
7. Knowl­er WC, Bar­rett-‍Con­nor E, Fowler SE, et al.; Di­a­betes Pre­ven­tion Pro­gram Re­search Group. Re­duc­tion in the in­ci­dence of type 2 di­a­betes with lifestyle in­ter­ven­tion or met­formin. N Engl J Med 2002;346:393–403
8. Tuomile­hto J, Lind­stro¨m J, Eriks­son JG, et al.; Finnish Di­a­betes Pre­ven­tion Study Group. Pre­ven­tion of type 2 di­a­betes mel­li­tus by changes in lifestyle among sub­jects with im­paired glu­cose tol­er­ance. N Engl J Med 2001;344: 1343–1350
9. Mei­jnikman AS, De Block CEM, Dirinck E, et al. Not per­form­ing an OGTT re­sults in significant underdi­ag­no­sis of (pre)di­a­betes in a high risk adult Cau­casian pop­u­la­tion. Int J Obes 2017;41: 1615–1620
10. Cowie CC, Rust KF, Byrd-‍Holt DD, et al. Preva­lence of di­a­betes and high risk for di­a­betes using A1C cri­te­ria in the U.S. pop­u­la­tion in 1988–2006. Di­a­betes Care 2010;33:562–568
11. Eck­hardt BJ, Holz­man RS, Kwan CK, Bagh­da­di J, Aberg JA. Gly­cat­ed hemoglobin A1c as screen­ing for di­a­betes mel­li­tus in HIV-‍in­fect­ed in­di­vid­u­als. AIDS Pa­tient Care STDS 2012;26:197–201
12. Kim PS, Woods C, Geor­goff P, et al. A1C un­der­es­ti­mates glycemia in HIV in­fec­tion. Di­a­betes Care 2009;32:1591–1593
13. Ar­sla­ni­an S, Bacha F, Grey M, Mar­cus MD, White NH, Zeitler P. Eval­u­a­tion and man­age­ment of youth-‍onset type 2 di­a­betes: a po­si­tion state­ment by the Amer­i­can Di­a­betes As­so­ci­a­tion. Di­a­betes Care 2018;41:2648–2668
14. Lacy ME, Welle­nius GA, Sum­n­er AE, Cor­rea A, Car­nethon MR, Liem RI, et al. As­so­ci­a­tion of sick­le cell trait with hemoglobin A1c in African Amer­i­cans. JAMA 2017;317:507–515
15. Wheel­er E, Leong A, Liu C-T, et al.; EPIC-‍CVD Con­sor­tium; EPIC-‍InterAct Con­sor­tium; Life­lines Co­hort Study. Im­pact of com­mon ge­net­ic de­ter­mi­nants of hemoglobin A1c on type 2 di­a­betes risk and di­ag­no­sis in an­ces­tral­ly di­verse pop­u­la­tions: a transeth­nic genome-‍wide metaanal­y­sis. PLoS Med 2017;14:e1002383
16. Ziemer DC, Kolm P, Wein­traub WS, et al. Glu­cose-‍inde­pen­dent, black-‍white dif­ferences in hemoglobin A1c lev­els: a cross-sec­tional anal­y­sis of 2 stud­ies. Ann In­tern Med 2010;152:770–777
17. Kumar PR, Bhansali A, Raviki­ran M, et al. Util­i­ty of gly­cat­ed hemoglobin in di­ag­nos­ing type 2 di­a­betes mel­li­tus: a com­mu­ni­ty-‍based study. J Clin En­docrinol Metab 2010;95:2832– 2835
18. Her­man WH. Are there clin­i­cal im­pli­ca­tions of racial dif­ferences in HbA1c? Yes, to not con­sid­er can do great harm! Di­a­betes Care 2016;39: 1458–1461
19. Her­man WH, Ma Y, Uwaifo G, et al.; Di­a­betes Pre­ven­tion Pro­gram Re­search Group. Dif­fer­ences in A1C by race and eth­nicity among pa­tients with im­paired glu­cose tol­er­ance in the Di­a­betes Pre­ven­tion Pro­gram. Di­a­betes Care 2007;30: 2453–2457
20. Bergen­stal RM, Gal RL, Con­nor CG, et al.; T1D Ex­change Racial Dif­fer­ences Study Group. Racial dif­ferences in the re­la­tion­ship of glu­cose con­cen­tra­tions and hemoglobin A1c lev­els. Ann In­tern Med 2017;167:95–102
21. Selvin E, Steffes MW, Bal­lan­tyne CM, Hoogeveen RC, Core­sh J, Bran­cati FL. Racial dif­ferencesin glycemicmark­ers: across-sec­tional anal­y­sis of com­mu­ni­ty-‍based data. Ann In­tern Med 2011;154:303–309
22. Her­man WH, Dun­gan KM, Wolf­fen­but­tel BHR, et al. Racial and eth­nic dif­ferences in mean plas­ma glu­cose, hemoglobin A1c, and 1,5-‍an­hy­droglu­ci­tol in over 2000 pa­tients with type 2 di­a­betes. J Clin En­docrinol Metab 2009; 94:1689–1694
23. Selvin E, Rawl­ings AM, Bergen­stal RM, Core­sh J, Bran­cati FL. No racial dif­ferences in the as­so­ci­a­tion of gly­cat­ed hemoglobin with kid­ney dis­ease and car­dio­vas­cu­lar out­comes. Di­a­betes Care 2013;36:2995–3001
24. Selvin E. Are there clin­i­cal im­pli­ca­tions of racial dif­ferences in HbA1c? A dif­ference, to be a dif­ference, must make a dif­ference. Di­a­betes Care 2016;39:1462–1467
25. Pa­ter­son AD. HbA1c for type 2 di­a­betes di­ag­no­sis in Africans and African Amer­i­cans: per­sonalized medicine NOW! PLoS Med 2017; 14:e1002384
26. Cap­pelli­ni MD, Fiorel­li G. Glu­cose-‍6-‍phos­phate de­hy­dro­ge­nase deficien­cy. Lancet 2008;371:64–74
27. Pico´n MJ, Murri M, Mun~oz A, Ferna´ndez-‍Garc´ıa JC, Gomez-‍Huelgas R, Tina­hones FJ. Hemoglobin A1c ver­sus oral glu­cose tol­er­ance test in post­par­tum di­a­betes screen­ing. Di­a­betes Care 2012;35:1648–1653
28. Go¨bl CS, Bozkurt L, Yarragu­di R, Tura A, Paci­ni G, Kautzky-‍Willer A. Is early post­par­tum HbA1c an ap­pro­pri­ate risk pre­dic­tor after preg­nan­cy with ges­ta­tional di­a­betes mel­li­tus? Acta Di­a­betol 2014;51:715–722
29. Megia A, Na¨f S, Her­ranz L, et al. The use­ful­ness of HbA1c in post­par­tum reclas­sification of ges­ta­tional di­a­betes. BJOG 2012;119:891–894
30. Welsh KJ, Kirk­man MS, Sacks DB. Role of gly­cat­ed pro­teins in the di­ag­no­sis and man­age­ment of di­a­betes: re­search gaps and fu­ture di­rec­tions. Di­a­betes Care 2016;39:1299–1306
31. Kim C, Bullard KM, Her­man WH, Beck­les GL. As­so­ci­a­tion be­tween iron deficien­cy and A1C lev­els among adults with­out di­a­betes in the Na­tion­al Health and Nu­tri­tion Ex­am­i­na­tion Sur­vey, 1999-2006. Di­a­betes Care 2010;33:780–785
32. Selvin E, Wang D, Mat­sushi­ta K, Grams ME, Core­sh J. Prog­nos­tic im­pli­ca­tions of singlesam­ple confirma­to­ry test­ing for undi­ag­nosed di­a­betes: a prospec­tive co­hort study. Ann In­tern Med 2018;169:156–164
33. Dabe­lea D, Mayer-‍Davis EJ, Say­dah S, et al.; SEARCH for Di­a­betes in Youth Study. Preva­lence of type 1 and type 2 di­a­betes among chil­dren and ado­les­cents from 2001 to 2009. JAMA 2014;311: 1778–1786
34. Ziegler AG, Rew­ers M, Simell O, et al. Se­ro­con­ver­sion to mul­ti­ple islet au­toan­ti­bod­ies and risk of pro­gres­sion to di­a­betes in chil­dren. JAMA 2013;309:2473–2479
35. Sosenko JM, Skyler JS, Palmer JP, et al.; Type 1 Di­a­betes Tri­al­Net Study Group; Di­a­betes Pre­ven­tion Trial-‍Type 1 Study Group. The pre­diction of type 1 di­a­betes by mul­ti­ple autoan­ti­body lev­els and their in­cor­po­ra­tion into an autoan­ti­body risk score in rel­a­tives of type 1 di­a­bet­ic pa­tients. Di­a­betes Care 2013;36:2615–2620
36. Steck AK, Vehik K, Boni­fa­cio E, et al.; TEDDY Study Group. Pre­dic­tors of pro­gres­sion from the ap­pearance of islet au­toan­ti­bod­ies to early child­hood di­a­betes: The En­vi­ron­men­tal De­ter­mi­nants of Di­a­betes in the Young (TEDDY). Di­a­betes Care 2015;38:808–813
37. Orban T, Sosenko JM, Cuth­bert­son D, et al.; Di­a­betes Pre­ven­tion Trial-‍Type 1 Study Group. Pan­cre­at­ic islet au­toan­ti­bod­ies as pre­dic­tors of type 1 di­a­betes in the Di­a­betes Pre­ven­tion Trial–Type 1. Di­a­betes Care 2009;32:2269– 2274
38. Genuth S, Al­ber­ti KG, Ben­nett P, et al.; Ex­pert Com­mit­tee on the Di­ag­no­sis and Clas­sification of Di­a­betes Mel­li­tus. Fol­low-‍up re­port on the di­ag­no­sis of di­a­betes mel­li­tus. Di­a­betes Care 2003; 26:3160–3167
39. Amer­i­can Di­a­betes As­so­ci­a­tion. Di­ag­no­sis and clas­sification of di­a­betes mel­li­tus. Di­a­betes Care 2011;34(Suppl. 1):S62–S69
40. Ex­pert Com­mit­tee on the Di­ag­no­sis and Clas­sification of Di­a­betes Mel­li­tus. Re­port of the Ex­pert Com­mit­tee on the Di­ag­no­sis and Clas­sification of Di­a­betes Mel­li­tus. Di­a­betes Care 1997;20:1183–1197
41. Zhang X, Gregg EW, Williamson DF, et al. A1C level and fu­ture risk of di­a­betes: a sys­tematic re­view. Di­a­betes Care 2010;33:1665–1673
42. Selvin E, Steffes MW, Zhu H, et al. Gly­cat­ed hemoglobin, di­a­betes, and car­dio­vas­cu­lar risk in nondi­a­bet­ic adults. N Engl J Med 2010;362: 800–811
43. Ack­er­mann RT, Cheng YJ, Williamson DF, Gregg EW. Iden­ti­fy­ing adults at high risk for di­a­betes and car­dio­vas­cu­lar dis­ease using hemoglobin A1c Na­tion­al Health and Nu­tri­tion Ex­am­i­na­tion Sur­vey 2005-2006. Am J Prev Med 2011;40:11–17
44. Di­a­betes Pre­ven­tion Pro­gram Re­search Group. HbA1c as a pre­dic­tor of di­a­betes and as an out­come in the Di­a­betes Pre­ven­tion Pro­gram: a ran­domized clin­i­cal trial. Di­a­betes Care 2015;38:51–58
45. Umpier­rez G, Ko­ry­tkows­ki M. Di­a­bet­ic emer­gen­cies - ke­toaci­do­sis, hy­per­gly­caemic hy­per­os­mo­lar state and hy­po­gly­caemia. Nat Rev En­docrinol 2016;12:222–232
46. Fa­di­ni GP, Bono­ra BM, Avog­a­ro A. SGLT2 in­hibitors and di­a­bet­ic ke­toaci­do­sis: data from the FDA Ad­verse Event Re­porting Sys­tem. Di­a­betologia 2017;60:1385–1389
47. Griffin SJ, Borch-‍Johnsen K, Davies MJ, et al. Ef­fect of early in­ten­sive mul­ti­fac­to­ri­al ther­a­py on 5-year car­dio­vas­cu­lar out­comes in in­di­vid­u­als with type 2 di­a­betes de­tected by screen­ing (AD­DI­TION-‍Eu­rope): a cluster-ran­domised trial. Lancet 2011;378:156–167
48. Her­man WH, Ye W, Griffin SJ, et al. Early de­tec­tion and treat­ment of type 2 di­a­betes re­duce car­dio­vas­cu­lar mor­bid­i­ty and mor­tal­i­ty: a sim­u­la­tion of the re­sults of the Anglo-‍Dan­ish-‍Dutch Study of In­ten­sive Treat­ment in Peo­ple with Screen-‍De­tect­ed Di­a­betes in Pri­ma­ry Care (AD­DI­TION-‍Eu­rope). Di­a­betes Care 2015;38: 1449–1455
49. Kahn R, Alperin P, Eddy D, et al. Age at ini­ti­a­tion and fre­quen­cy of screen­ing to de­tect type 2 di­a­betes: a cost-‍ef­fec­tiveness anal­y­sis. Lancet 2010;375:1365–1374
50. Arane­ta MRG, Kanaya A, Fu­ji­mo­to W, et al. Op­ti­mum BMI cut-‍points to screen Asian Amer­i­cans for type 2 di­a­betes: The UCSD Fil­ipino Health Study and the North Ko­ha­la Study [Ab­stract]. Di­a­betes 2014;63(Suppl. 1):A20
51. Hsu WC, Arane­ta MRG, Kanaya AM, Chi­ang JL, Fu­ji­mo­to W. BMI cut points to iden­tify at-‍risk Asian Amer­i­cans for type 2 di­a­betes screen­ing. Di­a­betes Care 2015;38:150–158
52. WHO Ex­pert Con­sul­ta­tion. Ap­pro­pri­ate body-‍mass index for Asian pop­u­la­tions and its im­pli­ca­tions for pol­i­cy and in­ter­ven­tion strate­gies. Lancet 2004;363:157–163
53. Menke A, Casagrande S, Geiss L, Cowie CC. Preva­lence of and trends in di­a­betes among adults in the Unit­ed States, 1988-2012. JAMA 2015;314:1021–1029
54. Cen­ters for Dis­ease Con­trol and Pre­ven­tion. Na­tion­al di­a­betes statis­tics re­port: es­ti­mates of di­a­betes and its bur­den in the Unit­ed States, 2017 [In­ternet]. Avail­able from https://www.cdc.gov/di­a­betes/data/statis­tics/statis­tics-re­port.html. Ac­cessed 20 Septem­ber 2018
55. Chiu M, Austin PC, Manuel DG, Shah BR, Tu JV. De­riv­ing eth­nic-‍specific BMI cut­off points for as­sess­ing di­a­betes risk. Di­a­betes Care 2011;34: 1741–1748
56. Er­ick­son SC, Le L, Za­kharyan A, et al. New-‍onset treat­ment-‍de­pen­dent di­a­betes mel­li­tus and hy­per­lipi­demia as­so­ci­at­ed with atyp­i­cal an­tipsy­chot­ic use in older adults with­out schizophre­nia or bipo­lar dis­or­der. J Am Geri­atr Soc 2012;60:474–479
57. John­son SL, Tabaei BP, Her­man WH. The efficacy and cost of al­ter­na­tive strate­gies for sys­tematic screen­ing for type 2 di­a­betes in the U.S. pop­u­la­tion 45–74 years of age. Di­a­betes Care 2005;28:307–311
58. Tabaei BP, Burke R, Con­stance A, et al. Com­mu­ni­ty-‍based screen­ing for di­a­betes in Michi­gan. Di­a­betes Care 2003;26:668–670
59. Lalla E, Kun­zel C, Bur­kett S, Cheng B, Lam­ster IB. Iden­tification of unrec­og­nized di­a­betes and pre-‍di­a­betes in a den­tal set­ting. J Dent Res 2011; 90:855–860
60. Lalla E, Cheng B, Kun­zel C, Bur­kett S, Lam­ster IB. Den­tal find­ings and iden­tification of undi­ag­nosed hy­per­glycemia. J Dent Res 2013;92:888– 892
61. Her­man WH, Tay­lor GW, Ja­cob­son JJ, Burke R, Brown MB. Screen­ing for predi­a­betes and type 2 di­a­betes in den­tal offices. J Pub­lic Health Dent 2015;75:175–182
62. Buse JB, Kauf­man FR, Lin­der B, Hirst K, El Ghorm­li L, Willi S; HEALTHY Study Group. Di­a­betes screen­ing with hemoglobin A1c ver­sus fast­ing plas­ma glu­cose in a multieth­nic mid­dle-‍school co­hort. Di­a­betes Care 2013;36:429–435
63. Ka­pa­dia C, Zeitler P; Drugs and Ther­a­peu­tics Com­mit­tee of the Pe­di­atric En­docrine So­ci­ety. Hemoglobin A1c mea­surement for the di­ag­no­sis of type 2 di­a­betes in chil­dren. Int J Pe­di­atr En­docrinol 2012;2012:31
64. Kester LM, Hey H, Han­non TS. Using hemoglobin A1c for predi­a­betes and di­a­betes di­ag­no­sis in ado­les­cents: can adult rec­om­men­da­tions be up­held for pe­di­atric use? J Ado­lesc Health 2012;50:321–323
65. Wu E-L, Kazzi NG, Lee JM. Cost-ef­fec­tiveness of screen­ing strate­gies for iden­tifying pe­di­atric di­a­betes mel­li­tus and dys­g­lycemia. JAMA Pe­di­atr 2013;167:32–39
66. Lawrence JM, Con­tr­eras R, Chen W, Sacks DA. Trends in the preva­lence of pre­ex­ist­ing di­a­betes and ges­ta­tional di­a­betes mel­li­tus among a racially/eth­nically di­verse pop­u­la­tion of preg­nant women, 1999–2005. Di­a­betes Care 2008;31:899–904
67. Poltavskiy E, Kim DJ, Bang H. Com­par­i­son of screen­ing scores for di­a­betes and predi­a­betes. Di­a­betes Res Clin Pract 2016;118:146–153
68. Hugh­es RCE, Rowan J, Willi­man J. Predi­a­betes in preg­nan­cy, can early in­ter­ven­tion im­prove out­comes? A fea­si­bil­i­ty study for a par­al­lel ran­domised clin­i­cal trial. BMJ Open 2018;8: e018493
69. McIn­tyre HD, Sacks DA, Bar­bour LA, et al. Is­sues with the di­ag­no­sis and clas­sification of hy­per­glycemia in early preg­nan­cy. Di­a­betes Care 2016;39:53–54
70. Noc­tor E, Crowe C, Car­mody LA, et al.; AT­LANTIC-‍DIP in­ves­ti­ga­tors. Abnor­mal glu­cose tol­er­ance post-ges­ta­tional di­a­betes mel­li­tus as defined by the In­ter­na­tion­al As­so­ci­a­tion of Di­a­betes and Preg­nan­cy Study Groups cri­te­ria. Eur J En­docrinol 2016;175:287–297
71. Kim C, New­ton KM, Knopp RH. Ges­ta­tion­al di­a­betes and the in­ci­dence of type 2 di­a­betes: a sys­tematic re­view. Di­a­betes Care 2002;25: 1862–1868
72. Rat­ner RE, Christophi CA, Met­zger BE, et al.; Di­a­betes Pre­ven­tion Pro­gram Re­search Group. Pre­ven­tion ofdi­a­betesinwomenwithahis­to­ry of ges­ta­tional di­a­betes: ef­fects of met­formin and lifestyle in­ter­ven­tions. J Clin En­docrinol Metab 2008;93:4774–4779
73. Aroda VR, Christophi CA, Edel­stein SL, et al.; Di­a­betes Pre­ven­tion Pro­gram Re­search Group. The ef­fect of lifestyle in­ter­ven­tion and met­formin on pre­venting or de­lay­ing di­a­betes among women with and with­out ges­ta­tional di­a­betes: the Di­a­betes Pre­ven­tion Pro­gram Out­comes Study 10-year fol­low-‍up. J Clin En­docrinol Metab 2015;100:1646–1653
74. Met­zger BE, Lowe LP, Dyer AR, et al.; HAPO Study Co­op­er­a­tive Re­search Group. Hy­per­glycemia and ad­verse preg­nan­cy out­comes. N Engl J Med 2008;358:1991–2002
75. Sacks DA, Had­den DR, Maresh M, et al.; HAPO Study Co­op­er­a­tive Re­search Group. Fre­quen­cy of ges­ta­tional di­a­betes mel­li­tus at col­lab­o­rat­ing cen­ters based on IADPSG con­sen­sus panel-‍rec­om­mend­ed cri­te­ria: the Hy­per­glycemia and Ad­verse Preg­nan­cy Out­come (HAPO) Study. Di­a­betes Care 2012;35:526–528
76. Lowe WL Jr, Scholtens DM, Lowe LP, et al.; HAPO Fol­low-‍up Study Co­op­er­a­tive Re­search Group. As­so­ci­a­tion of ges­ta­tional di­a­betes with ma­ter­nal dis­or­ders of glu­cose metabolism and child­hood adi­pos­i­ty. JAMA 2018;320:1005–016
77. Lan­don MB, Spong CY, Thom E, et al.; Eu­nice Kennedy Shriver Na­tion­al In­sti­tute of Child Health and Human De­vel­op­ment Ma­ter­nal-‍Fetal Medicine Units Net­work. A multicen­ter, ran­domized trial of treat­ment for mild ges­ta­tional di­a­betes. N Engl J Med 2009;361:1339–1348
78. Crowther CA, Hiller JE, Moss JR, McPhee AJ, Jef­fries WS, Robin­son JS; Aus­tralian Car­bo­hy­drate Intol­er­ance Study in Preg­nant Women (ACHOIS) Trial Group. Ef­fect of treat­ment of ges­ta­tional di­a­betes mel­li­tus on preg­nan­cy out­comes. N Engl J Med 2005; 352:2477–2486
79. Tam WH, Ma RCW, Ozaki R, et al. In utero ex­po­sure to ma­ter­nal hy­per­glycemia in­creas­es child­hood cardiometabol­ic risk in off­spring. Di­a­betes Care 2017;40:679–686
80. Lan­don MB, Rice MM, Varn­er MW, et al.; Eu­nice Kennedy Shriver Na­tion­al In­sti­tute of Child Health and Human De­vel­op­ment Ma­ter­nal-‍Fetal Medicine Units (MFMU) Net­work. Mild ges­ta­tional di­a­betes mel­li­tus and long-‍term child health. Di­a­betes Care 2015;38:445–452
81. Van­dorsten JP, Dod­son WC, Es­peland MA, et al. NIH con­sen­sus de­vel­op­ment con­fer­ence: di­ag­nos­ing ges­ta­tional di­a­betes mel­li­tus. NIH Con­sens State Sci State­ments 2013;29:1–31
82. Com­mit­tee on Prac­tice Bul­letins­dOb­stet­rics. Prac­tice Bul­letin No. 190: ges­ta­tional di­a­betes mel­li­tus. Ob­stet Gy­necol 2018;131:e49–e64
83. Dono­van L, Hartling L, Muise M, Guthrie A, Van­der­meer B, Dry­den DM. Screen­ing tests for ges­ta­tional di­a­betes: a sys­tematic re­view for the U.S. Pre­ven­tive Ser­vices Task Force. Ann In­tern Med 2013;159:115–122
84. Kha­lafal­lah A, Phuah E, Al-‍Barazan AM, et al. Gly­co­sy­lat­ed haemoglobin for screen­ing and di­ag­no­sis of ges­ta­tional di­a­betes mel­li­tus. BMJ Open 2016;6:e011059
85. Hor­vath K, Koch K, Jeitler K, et al. Ef­fects of treat­ment in women with ges­ta­tional di­a­betes mel­li­tus: sys­tematic re­view and meta-‍anal­y­sis. BMJ 2010;340:c1395
86. Car­pen­ter MW, Cous­tan DR. Cri­te­ria for screen­ing tests for ges­ta­tional di­a­betes. Am J Ob­stet Gy­necol 1982;144:768–773
87. Na­tion­al Di­a­betes Data Group. Clas­sification and di­ag­no­sis of di­a­betes mel­li­tus and other cat­e­gories of glu­cose intol­er­ance. Di­a­betes 1979; 28:1039–1057
88. Harp­er LM, Mele L, Lan­don MB, et al.; Eu­nice Kennedy Shriver Na­tion­al In­sti­tute of Child Health and Human De­vel­op­ment (NICHD) Ma­ter­nal-‍Fetal Medicine Units (MFMU) Net­work. Car­pen­ter-‍Cous­tan com­pared with Na­tion­al Di­a­betes Data Group cri­te­ria for di­ag­nos­ing ges­ta­tional di­a­betes. Ob­stet Gy­necol 2016;127:893–898
89. Wern­er EF, Pet­tk­er CM, Zuck­er­wise L, et al. Screen­ing for ges­ta­tional di­a­betes mel­li­tus: are the cri­te­ria pro­posed by the In­ter­na­tion­al As­so­ci­a­tion of the Di­a­betes and Preg­nan­cy Study Groups cost-‍ef­fec­tive? Di­a­betes Care 2012;35: 529–535
90. Duran A, Sa´enz S, Tor­re­jo´n MJ, et al. In­tro­duc­tion of IADPSG cri­te­ria for the screen­ing and di­ag­no­sis of ges­ta­tional di­a­betes mel­li­tus re­sults in im­proved preg­nan­cy out­comes at a lower cost in a large co­hort of preg­nant women: the St. Car­los Ges­ta­tion­al Di­a­betes Study. Di­a­betes Care 2014;37:2442–2450
91. Wei Y, Yang H, Zhu W, et al. In­ter­na­tion­al As­so­ci­a­tion of Di­a­betes and Preg­nan­cy Study Group cri­te­ria is suit­able for ges­ta­tional di­a­betes mel­li­tus di­ag­no­sis: fur­ther ev­i­dence from China. Chin Med J (Engl) 2014;127:3553–3556
92. Feld­man RK, Tieu RS, Ya­sumu­ra L. Ges­ta­tion­al di­a­betes screen­ing: the In­ter­na­tion­al As­so­ci­a­tion of the Di­a­betes and Preg­nan­cy Study Groups com­pared with Car­pen­ter-‍Cous­tan screen­ing. Ob­stet Gy­necol 2016;127:10–17
93. Ethridge JK Jr, Cata­lano PM, Wa­ters TP. Peri­na­tal out­comes as­so­ci­at­ed with the di­ag­no­sis of ges­ta­tional di­a­betes made by the In­ter­na­tion­al As­so­ci­a­tion of the Di­a­betes and Preg­nan­cy Study Groups cri­te­ria. Ob­stet Gy­necol 2014;124: 571–578
94. Mayo K, Melamed N, Van­den­berghe H, Berg­er H. The im­pact of adop­tion of the in­ter­na­tion­al as­so­ci­a­tion of di­a­betes in preg­nan­cy study group cri­te­ria for the screen­ing and di­ag­no­sis of ges­ta­tional di­a­betes. Am J Ob­stet Gy­necol 2015;212:224.e1–224.e9
95. Moran A, Pil­lay K, Beck­er D, Grana­dos A, Hameed S, Ac­eri­ni CL. ISPAD Clin­i­cal Prac­tice Con­sensus Guide­lines 2018: man­age­ment of cys­tic fibro­sis-‍re­lat­ed di­a­betes in chil­dren and ado­les­cents. Pe­di­atr Di­a­betes 2018;19(Suppl. 27):64–74
96. Main­guy C, Bel­lon G, De­laup V, et al. Sen­si­tiv­i­ty and specificity of dif­ferent meth­ods for cys­tic fibro­sis-‍re­lat­ed di­a­betes screen­ing: is the oral glu­cose tol­er­ance test still the stan­dard? J Pe­di­atr En­docrinol Metab 2017; 30:27–35
97. Ode KL, Moran A. New in­sights into cys­tic fibro­sis-‍re­lat­ed di­a­betes in chil­dren. Lancet Di­a­betes En­docrinol 2013;1:52–58
98. Moran A, Dunitz J, Nathan B, Saeed A, Holme B, Thomas W. Cys­tic fibro­sis–re­lat­ed di­a­betes: cur­rent trends in preva­lence, in­ci­dence, and mor­tal­i­ty. Di­a­betes Care 2009;32:1626–1631
99. Moran A, Pekow P, Grover P, et al.; Cys­tic Fibro­sis Re­lat­ed Di­a­betes Ther­a­py Study Group. In­sulin ther­a­py to im­prove BMI in cys­tic fibro­sis– re­lat­ed di­a­betes with­out fast­ing hy­per­glycemia: re­sults of the Cys­tic Fibro­sis Re­lat­ed Di­a­betes Ther­a­py Trial. Di­a­betes Care 2009;32: 1783–1788
100. Onady GM, Stolfi A. In­sulin and oral agents for man­ag­ing cys­tic fibro­sis–re­lat­ed di­a­betes. Cochrane Database Syst Rev 2016;4:CD004730
101. Moran A, Brun­zell C, Cohen RC, et al.; CFRD Guide­lines Com­mit­tee. Clin­i­cal care guide­lines for cys­tic fibro­sis–re­lat­ed di­a­betes: a po­si­tion state­ment of the Amer­i­can Di­a­betes As­so­ci­a­tion and a clin­i­cal prac­tice guide­line of the Cys­tic Fibro­sis Foun­da­tion, en­dorsed by the Pe­di­atric En­docrine So­ci­ety. Di­a­betes Care 2010;33:2697–2708
102. Moran A, Pil­lay K, Beck­er DJ, Ac­eri­ni CL; In­ter­na­tion­al So­ci­ety for Pe­di­atric and Ado­les­cent Di­a­betes. ISPAD Clin­i­cal Prac­tice Con­sensus Guide­lines 2014. Man­age­ment of cys­tic fibrosi-‍re­lat­ed di­a­betes in chil­dren and ado­les­cents. Pe­di­atr Di­a­betes 2014;15(Suppl. 20):65–76
103. Sharif A, Heck­ing M, de Vries APJ, et al. Pro­ceed­ings from an in­ter­na­tion­al con­sen­sus meet­ing on posttrans­plan­ta­tion di­a­betes mel­li­tus: rec­om­men­da­tions and fu­ture di­rec­tions. Am J Trans­plant 2014;14:1992–2000
104. Heck­ing M, Wer­zowa J, Haidinger M, et al. Novel views on new-‍onset di­a­betes after trans­plan­ta­tion: de­vel­op­ment, pre­ven­tion and treat­ment. Nephrol Dial Trans­plant 2013;28:550–566
105. Ramirez SC, Maaske J, Kim Y, et al. The as­so­ci­a­tion be­tween glycemic con­trol and clin-‍ical out­comes after kid­ney trans­plan­ta­tion. En-‍docr Pract 2014;20:894–900
106. Thomas MC, Moran J, Math­ew TH, Russ GR, Rao MM. Early peri-‍op­er­a­tive hy­per­gly­caemia and renal al­lo­graft re­jec­tion in pa­tients with­out di­a­betes. BMC Nephrol 2000;1:1
107. Chakkera HA, Weil EJ, Cas­tro J, et al. Hy­per­glycemia dur­ing the im­me­di­ate pe­ri­od after kid­ney trans­plan­ta­tion. Clin J Am Soc Nephrol 2009;4:853–859
108. Wal­lia A, Il­luri V, Molitch ME. Di­a­betes care after trans­plant: defini­tions, risk fac­tors, and clin­i­cal man­age­ment. Med Clin North Am 2016;100: 535–550
109. Sharif A, Moore RH, Ba­boolal K. The use of oral glu­cose tol­er­ance tests to risk strat­i­fy for new-‍onset di­a­betes after trans­plan­ta­tion: an underdi­ag­nosed phe­nomenon. Trans­plantation 2006;82:1667–1672
110. Heck­ing M, Kainz A, Wer­zowa J, et al. Glu­cose metabolism after renal trans­plan­ta­tion. Di­a­betes Care 2013;36:2763–2771
111. Galin­do RJ, Fried M, Breen T, Tam­ler R. Hy­per­glycemia man­age­ment in pa­tients with posttrans­plan­ta­tion di­a­betes. En­docr Pract 2016;22:454–465
112. Jenssen T, Hart­mann A. Emerg­ing treat­ments for post-‍trans­plan­ta­tion di­a­betes mel­li­tus. Nat Rev Nephrol 2015;11:465–477
113. Thomas MC, Math­ew TH, Russ GR, Rao MM, Moran J. Early peri-‍op­er­a­tive gly­caemic con­trol and al­lo­graft re­jec­tion in pa­tients with di­a­betes mel­li­tus: a pilot study. Trans­plantation 2001;72:1321–1324
114. Kuri­an B, Joshi R, Hel­muth A. Ef­fectiveness and long-‍term safe­ty of thi­a­zo­lidine­diones and met­formin in renal trans­plant re­cip­i­ents. En­docr Pract 2008;14:979–984
115. Budde K, Neu­may­er H-H, Fritsche L, Su­low­icz W, Stom­por T, Eck­land D. The phar­ma­coki­net­ics of pi­ogli­ta­zone in pa­tients with im­paired renal func­tion. Br J Clin Phar­ma­col 2003; 55:368–374
116. Luther P, Bald­win D Jr. Pi­ogli­ta­zone in the man­age­ment of di­a­betes mel­li­tus after trans­plan­ta­tion. Am J Trans­plant 2004;4:2135– 2138
117. Strøm Halden TA, ° As­berg A, Vik K, Hart­mann A, Jenssen T. Short-‍term ef­fi­ca­cy and safe­ty of sitagliptin treat­ment in longterm sta­ble renal re­cip­i­ents with new-‍onset di­a­betes after trans­plan­ta­tion. Nephrol Dial Trans­plant 2014;29:926–933
118. Lane JT, Ode­gaard DE, Haire CE, Col­lier DS, Wren­shall LE, Stevens RB. Sitagliptin ther­a­py in kid­ney trans­plant re­cip­i­ents with new-‍onset di­a­betes after trans­plan­ta­tion. Trans­plantation 2011;92:e56–e57
119. Car­mody D, Støy J, Gree­ley SA, Bell GI, Philip­son LH. A clin­i­cal guide to mono­genic di­a­betes. In Ge­net­ic Di­ag­no­sis of En­docrine Dis­or­ders. 2nd ed. Weiss RE, Refetoff S, Eds. Philadel­phia, PA, El­se­vi­er, 2016
120. De Fran­co E, Flana­gan SE, Houghton JAL, et al. The ef­fect of early, com­pre­hen­sive ge­nom­ic test­ing on clin­i­cal care in neona­tal di­a­betes: an in­ter­na­tion­al co­hort study. Lancet 2015;386: 957–963
121. Ur­bano­va´ J, Rypa´ckova´ B, Procha´zkova´ Z, et al. Pos­i­tiv­i­ty for islet cell au­toan­ti­bod­ies in pa­tients with mono­genic di­a­betes is as­so­ci­at­ed with later di­a­betes onset and high­er HbA1c level. Di­a­bet Med 2014;31:466–471
122. Nay­lor RN, John PM, Winn AN, et al. Cost-ef­fec­tiveness of MODY ge­net­ic test­ing: trans­lat­ing ge­nom­ic ad­vances into prac­ti­cal health ap­pli­ca­tions. Di­a­betes Care 2014;37: 202–209
123. Shields BM, Shep­herd M, Hud­son M, et al.; UNIT­ED study team. Pop­u­la­tion-‍based as­sess­ment of a biomark­er-‍based screen­ing path­way to aid di­ag­no­sis of mono­genic di­a­betes in young-‍onset pa­tients. Di­a­betes Care 2017;40:1017– 1025
124. Hat­ter­s­ley A, Bru­in­ing J, Shield J, Njol­stad P, Don­aghue KC. The di­ag­no­sis and man­age­ment of mono­genic di­a­betes in chil­dren and ado­les­cents. Pe­di­atr Di­a­betes 2009;10(Suppl. 12):33– 42
125. Rubio-‍Cabezas O, Hat­ter­s­ley AT, Njølstad PR, et al.; In­ter­na­tion­al So­ci­ety for Pe­di­atric and Ado­les­cent Di­a­betes. ISPAD Clin­i­cal Prac­tice Con­sensus Guide­lines 2014. The di­ag­no­sis and man­age­ment of mono­genic di­a­betes in chil­dren and ado­les­cents. Pe­di­atr Di­a­betes 2014;15 (Suppl. 20):47–64
126. Gree­ley SAW, Nay­lor RN, Philip­son LH, Bell GI. Neona­tal di­a­betes: an ex­pan­ding list of genes al­lows for im­proved di­ag­no­sis and treat­ment. Curr Diab Rep 2011;11:519–532